말기 신부전(ESRD) 시장 : 치료법별, 액세스 형태별, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The End Stage Renal Disease Market is projected to grow by USD 164.97 billion at a CAGR of 15.26% by 2032.

End Stage Renal Disease Market Executive Summary

End Stage Renal Disease (ESRD), also referred to as kidney failure or end-stage kidney disease, represents the most advanced stage of chronic kidney disease and requires renal replacement therapy through hemodialysis, peritoneal dialysis, or kidney transplantation. The ESRD landscape is shaped by the global rise in diabetes, hypertension, obesity, cardiovascular disease, and population aging, all of which are well-documented risk factors for chronic kidney disease progression.

The ESRD market is strategically important because it combines essential life-sustaining care with long-term treatment intensity, recurring consumables demand, specialized dialysis equipment, transplant services, and growing digital health integration. Health systems are prioritizing earlier CKD detection, home dialysis adoption, vascular access optimization, anemia management, and transplant capacity expansion to reduce avoidable hospitalization and improve survival, quality of life, and cost efficiency.

Transformative Shifts in the ESRD Landscape

The ESRD landscape is undergoing a measurable shift from facility-centered dialysis toward patient-centered kidney care models. Home hemodialysis and peritoneal dialysis are gaining policy attention because they can reduce travel burden, support treatment flexibility, and align with value-based care objectives when patient selection, training, and remote monitoring are robust.

At the same time, kidney care providers are moving upstream. Integrated CKD management, earlier nephrology referral, cardiovascular risk control, and diabetes management are increasingly viewed as essential to slowing progression to ESRD. Device manufacturers, dialysis providers, pharmaceutical developers, transplant centers, and payers are converging around care pathways that emphasize prevention, modality choice, patient education, and measurable outcomes rather than treatment volume alone.

Cumulative Impact of Artificial Intelligence in ESRD Care

Artificial intelligence is becoming a practical enabler across ESRD prevention, treatment, and operations. Predictive analytics can help identify patients at high risk of CKD progression, hospitalization, fluid overload, vascular access failure, or missed dialysis sessions by using electronic health records, laboratory trends, medication history, and device-generated data. These applications support earlier intervention and more consistent care coordination.

AI is also influencing dialysis clinic productivity, home dialysis support, transplant evaluation, and population health management. Algorithms can assist with scheduling, supply forecasting, treatment personalization, imaging review, and patient engagement. However, the cumulative impact depends on transparent validation, bias monitoring, cybersecurity, clinician oversight, and compliance with health data regulations, because ESRD patients are clinically complex and often have multiple comorbidities.

Key Regional Insights: ESRD Growth Across Global Markets

Asia-Pacific carries a substantial share of the global kidney disease burden due to the scale of China and India, rapid urbanization, rising diabetes prevalence, and expanding access to dialysis infrastructure. Japan, Australia, and South Korea have mature renal registries and high standards for renal replacement therapy, while emerging Asia-Pacific markets are focused on affordability, workforce expansion, dialysis reimbursement, and broader peritoneal dialysis access.

North America remains one of the most advanced ESRD markets, supported by established reimbursement systems, dialysis networks, transplant programs, and clinical research capacity. In the United States, national renal data show that more than 800,000 people live with end-stage kidney disease, making cost containment, home dialysis growth, vascular access quality, and transplant access central policy priorities. Canada emphasizes publicly funded care, home modalities, provincial renal programs, and equitable access across geographically dispersed populations.

Europe benefits from universal or near-universal health coverage, strong nephrology societies, renal registries, and quality-based care models. Western Europe has mature dialysis and transplant infrastructure, while parts of Eastern Europe continue to invest in capacity and modernization. Latin America shows rising ESRD demand led by Brazil and Mexico, but access varies by payer structure, geography, dialysis center availability, and specialist capacity. The Middle East, particularly GCC countries, is investing in advanced dialysis centers and transplant services in response to high diabetes and obesity rates. Africa remains the most access-constrained region, with dialysis concentrated in urban centers and affordability limiting continuity of treatment in many countries.

Key Group Insights: ESRD Demand Across Strategic Blocs

ASEAN countries are experiencing rising ESRD demand as diabetes and hypertension increase across urbanizing populations. Singapore and Malaysia have comparatively developed kidney care systems, while Indonesia, the Philippines, Thailand, and Vietnam are expanding dialysis coverage under different public insurance and private-provider models. The region's opportunity lies in scalable dialysis networks, nephrology workforce development, lower-cost consumables, and home-based care pathways that reduce travel and facility burden.

The GCC is characterized by high metabolic disease prevalence, government-backed healthcare investment, and increasing interest in domestic specialty care capacity. ESRD services in Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman are being shaped by public-sector modernization, private partnerships, dialysis infrastructure upgrades, and transplant program development. The European Union benefits from regulatory harmonization, cross-border clinical collaboration, and established renal data systems, supporting device quality, pharmacovigilance, evidence-based reimbursement, and consistent standards of renal replacement therapy.

BRICS countries represent a major share of global ESRD demand because of their population scale and growing noncommunicable disease burden. China, India, and Brazil are especially important for dialysis volume growth and local manufacturing strategies, while Russia and South Africa highlight the need for regional capacity balancing and reliable renal care access. G7 markets lead in clinical innovation, reimbursement sophistication, AI-enabled care management, home dialysis policy support, and transplant research. NATO is not a healthcare bloc, but many NATO members have advanced renal infrastructure and shared resilience priorities for medical supply chains, cybersecurity, emergency preparedness, and continuity of life-sustaining dialysis services.

Key Country Insights: ESRD Priorities in Major Markets

The United States is one of the world's most commercially significant ESRD markets, with national renal data reporting more than 800,000 people living with end-stage kidney disease and Medicare carrying a disproportionate share of ESRD spending. Canada's kidney care model emphasizes public coverage, provincial renal networks, home dialysis, and transplant coordination. Mexico faces growing ESRD demand linked to diabetes and uneven access across public and private systems, while Brazil operates one of Latin America's largest dialysis systems with substantial public reimbursement involvement and expanding nephrology capacity.

In Europe, the United Kingdom focuses on NHS-led renal networks, home therapies, vascular access management, and transplant services. Germany has a large dialysis population supported by advanced provider infrastructure and medical technology adoption. France maintains strong reimbursement coverage and organized nephrology care, while Italy and Spain combine mature dialysis services with active transplant programs and regional care coordination. Russia's ESRD market is shaped by large geography, regional access variation, and continuing modernization of dialysis capacity.

In Asia-Pacific, China is expanding dialysis access, domestic device production, hospital-based nephrology services, and chronic disease management as diabetes and hypertension prevalence rise. India has substantial unmet need, with affordability, insurance coverage, nephrologist availability, and dialysis center distribution remaining decisive market factors. Japan has one of the world's most mature dialysis systems and a highly aged ESRD population, creating demand for quality, safety, infection control, and efficiency. Australia emphasizes home dialysis, indigenous health equity, remote care delivery, and transplant access, while South Korea combines strong hospital infrastructure, high technology adoption, and national insurance support for renal replacement therapy.

Actionable Recommendations for ESRD Industry Leaders

Industry leaders should prioritize integrated kidney care models that identify high-risk CKD patients before ESRD onset, strengthen referral pathways, and support modality education. Providers and payers can improve outcomes by expanding home dialysis training, remote patient monitoring, nutritional support, medication adherence programs, vascular access planning, anemia management, and cardiovascular risk reduction.

Manufacturers and digital health developers should design ESRD solutions around clinical workflow integration, interoperability, cybersecurity, usability, and evidence generation. Partnerships with health systems, nephrology groups, transplant centers, and public agencies can support scalable adoption. In access-constrained markets, leaders should focus on cost-efficient equipment, reliable consumables supply, local service networks, preventive maintenance, and workforce training to improve continuity of care.

Research Methodology for ESRD Market Analysis

This executive summary is built on a structured methodology that triangulates publicly available clinical, regulatory, epidemiological, reimbursement, and industry data. Sources considered include renal registries, national health agencies, peer-reviewed nephrology literature, international health organizations, payer policy documents, regulatory publications, and expert interpretation of market dynamics.

The analysis emphasizes verified indicators such as ESRD prevalence, dialysis access, transplant infrastructure, chronic disease burden, reimbursement models, technology adoption, care delivery models, and regional renal care capacity. Data points are cross-checked for consistency, and unsupported promotional claims are excluded. The methodology combines top-down assessment of macro health trends with bottom-up review of treatment modalities, care settings, patient needs, and stakeholder behavior.

Conclusion: Future Outlook for the ESRD Market

The ESRD market is expanding in strategic importance as chronic kidney disease, diabetes, hypertension, and population aging increase pressure on health systems worldwide. Dialysis remains the core treatment foundation, while transplant access, home-based therapy, AI-enabled care management, remote monitoring, and integrated CKD prevention are shaping the next phase of market development.

Organizations that combine clinical evidence, patient-centered design, operational efficiency, and regional access strategies will be best positioned to compete. The strongest opportunities will emerge where stakeholders can reduce progression risk, improve treatment continuity, expand modality choice, and deliver measurable outcomes across diverse healthcare systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. End Stage Renal Disease Market, by Treatment Modality

• 7.1. Hemodialysis
  • 7.1.1. Home
  • 7.1.2. Incenter
• 7.2. Peritoneal Dialysis
  • 7.2.1. Continuous Ambulatory Peritoneal Dialysis
  • 7.2.2. Continuous Cycling Peritoneal Dialysis
• 7.3. Transplant
  • 7.3.1. Deceased Donor
  • 7.3.2. Living Donor

8. End Stage Renal Disease Market, by Access Type

• 8.1. Arteriovenous Fistula
• 8.2. Central Venous Catheter
• 8.3. Synthetic Graft

9. End Stage Renal Disease Market, by End User

• 9.1. Dialysis Centers
• 9.2. Home Care Settings
• 9.3. Hospitals

10. End Stage Renal Disease Market, by Region

• 10.1. Asia-Pacific
• 10.2. North America
• 10.3. Latin America
• 10.4. Europe
• 10.5. Middle East
• 10.6. Africa

11. End Stage Renal Disease Market, by Group

• 11.1. ASEAN
• 11.2. GCC
• 11.3. European Union
• 11.4. BRICS
• 11.5. G7
• 11.6. NATO

12. End Stage Renal Disease Market, by Country

• 12.1. United States
• 12.2. Canada
• 12.3. Mexico
• 12.4. Brazil
• 12.5. United Kingdom
• 12.6. Germany
• 12.7. France
• 12.8. Russia
• 12.9. Italy
• 12.10. Spain
• 12.11. China
• 12.12. India
• 12.13. Japan
• 12.14. Australia
• 12.15. South Korea

13. Competitive Landscape

• 13.1. Market Concentration Analysis, 2025
  • 13.1.1. Concentration Ratio (CR)
  • 13.1.2. Herfindahl Hirschman Index (HHI)
• 13.2. Recent Developments & Impact Analysis, 2025
• 13.3. Product Portfolio Analysis, 2025
• 13.4. Benchmarking Analysis, 2025

14. Company Profiles

• 14.1. AngioDynamics Inc.
• 14.2. Asahi Kasei Corporation
• 14.3. B. Braun Melsungen AG
• 14.4. Baxter International Inc.
• 14.5. Cantel Medical Corp.
• 14.6. DaVita Inc.
• 14.7. Dialysis Clinic Inc.
• 14.8. Fresenius Medical Care AG & Co. KGaA
• 14.9. Medtronic plc
• 14.10. Nipro Corporation
• 14.11. NxStage Medical Inc.
• 14.12. Outset Medical Inc.
• 14.13. Rockwell Medical Inc.
• 14.14. Satellite Healthcare Inc.
• 14.15. U.S. Renal Care Inc.